Related Experiment Video
Updated: Aug 17, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer
C Paul1, D C Skegg, G F Spears
1Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand.
Objective:
To determine whether use of the injectable contraceptive depot medroxyprogesterone acetate (Depo-Provera) affects the risk of breast cancer in women.
Design:
A population based case-control study.
Setting:
Nationwide community study.
Subjects:
891 Women aged 25-54 with newly diagnosed breast cancer were compared with 1864 women selected at random from the electoral rolls.
Intervention:
Women were interviewed by telephone about past use of contraceptives and about possible risk factors for breast cancer.
Main Outcome Measure:
Relative risk of breast cancer in women who had used medroxyprogesterone.
Results:
Medroxyprogesterone had been used by 110 patients and 252 controls. Overall, the relative risk of breast cancer associated with any duration of use was 1.0 (95% confidence interval 0.80 to 1.3). In women aged 25-34 the relative risk was 2.0 (1.0 to 3.8). The relative risk was highest in women aged 25-34 who had used the drug for six years or longer, although there were few women in this category. Women who had used it for two years or longer before age 25 had an increased risk of breast cancer (relative risk 4.6; 1.4 to 15.1).
Conclusion:
Despite the lack of an overall association these findings suggest that medroxyprogesterone may increase the risk of breast cancer in young women.
More Related Videos
06:18An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
13:43Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models
Published on: April 1, 2022
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer Prevention
Some...
Cancer Prevention
Some...
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Birth Control Methods
Intrauterine Drug Delivery Systems